Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jules Bordet Institute
Evaluation of the safety and the efficacy of a combination of oxaliplatin and 5FU (Folfox) in patients with ovarian carcinoma relapsing either after platinum-combined regimen.
The Folfox regimen is administered every 14 days. Evaluation of the toxicity is performed at each cycle and evaluation of the efficacy every 4 cycles of chemotherapy.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
ovarian carcinoma relapse
You may not be if
neurotoxicity grade III renal clearance \< 60 ml/min
